Breast Cancer Recurrent
18
6
7
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.6%
1 terminated out of 18 trials
87.5%
+1.0% vs benchmark
17%
3 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Thermotherapy in Addition to SOC Palliative Radiotherapy
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
GISEL:Registry of Breast Cancer Patients Treated With ECT
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
18F-FDG PET/CT Imaging for Breast Cancer
EpCAM CAR-T for Treatment of Advanced Solid Tumors
Registry of Local Recurrences After Breast-conserving Surgery
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
Prolonged Nightly Fasting in Breast Cancer Survivors
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT